» Articles » PMID: 38271991

Enhanced Antimalarial and Antisequestration Activity of Methoxybenzenesulfonate-Modified Biopolymers and Nanoparticles for Tackling Severe Malaria

Overview
Authors
Affiliations
Soon will be listed here.
Abstract

Severe malaria is a life-threatening condition that is associated with a high mortality. Severe infections are mediated primarily by high parasitemia and binding of infected red blood cells (iRBCs) to the blood vessel endothelial layer, a process known as sequestration. Here, we show that including the 5-amino-2-methoxybenzenesulfonate (AMBS) chemical modification in soluble biopolymers (polyglutamic acid and heparin) and poly(acrylic acid)-exposing nanoparticles serves as a universal tool to introduce a potent parasite invasion inhibitory function in these materials. Importantly, the modification did not add or eliminated (for heparin) undesired anticoagulation activity. The materials protected RBCs from invasion by various parasite strains, employing both major entry pathways. Two further strains, which either expose ligands for chondroitin sulfate A (CSA) or intercellular adhesion molecule 1 (ICAM-1) on iRBCs, were tested in antisequestration assays due to their relevance in placental and cerebral malaria, respectively. Antisequestration activity was found to be more efficacious with nanoparticles gold-standard soluble biopolymers (CSA and heparin) against both strains, when tested on receptor-coated dishes. The nanoparticles also efficiently inhibited and reversed the sequestration of iRBCs on endothelial cells. First, the materials described herein have the potential to reduce the parasite burden by acting at the key multiplication stage of reinvasion. Second, the antisequestration ability could help remove iRBCs from the blood vessel endothelium, which could otherwise cause vessel obstruction, which in turn can lead to multiple organ failure in severe malaria infections. This approach represents a further step toward creation of adjunctive therapies for this devastating condition to reduce morbidity and mortality.

Citing Articles

Pathogen-binding nanoparticles to inhibit host cell infection by heparan sulfate and sialic acid dependent viruses and protozoan parasites.

Najer A Smart Med. 2024; 3(2):e20230046.

PMID: 39188697 PMC: 11235646. DOI: 10.1002/SMMD.20230046.


Innovative Approaches for Drug Discovery: Quantifying Drug Distribution and Response with Raman Imaging.

Dunnington E, Wong B, Fu D Anal Chem. 2024; 96(20):7926-7944.

PMID: 38625100 PMC: 11108735. DOI: 10.1021/acs.analchem.4c01413.

References
1.
Memvanga P, Nkanga C . Liposomes for malaria management: the evolution from 1980 to 2020. Malar J. 2021; 20(1):327. PMC: 8313885. DOI: 10.1186/s12936-021-03858-0. View

2.
Bhide A, Surve D, Jindal A . Nanocarrier based active targeting strategies against erythrocytic stage of malaria. J Control Release. 2023; 362:297-308. DOI: 10.1016/j.jconrel.2023.08.043. View

3.
Pouvelle B, Fusai T, Lepolard C, Gysin J . Biological and biochemical characteristics of cytoadhesion of Plasmodium falciparum-infected erythrocytes to chondroitin-4-sulfate. Infect Immun. 1998; 66(10):4950-6. PMC: 108613. DOI: 10.1128/IAI.66.10.4950-4956.1998. View

4.
Introini V, Govendir M, Rayner J, Cicuta P, Bernabeu M . Biophysical Tools and Concepts Enable Understanding of Asexual Blood Stage Malaria. Front Cell Infect Microbiol. 2022; 12:908241. PMC: 9192966. DOI: 10.3389/fcimb.2022.908241. View

5.
Fried M, Duffy P . Adherence of Plasmodium falciparum to chondroitin sulfate A in the human placenta. Science. 1996; 272(5267):1502-4. DOI: 10.1126/science.272.5267.1502. View